{
    "clinical_study": {
        "@rank": "8375", 
        "acronym": "GATE I", 
        "arm_group": [
            {
                "arm_group_label": "Sodium oxybate (SMO)", 
                "arm_group_type": "Experimental", 
                "description": "Patients randomized to the first arm of the study will receive:\nSMO (sodium oxybate 175 mg/ml suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10 (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml);\nplacebo (tablets): 1 tablet at 8.00 a.m., 1 tablet at 12.00 p.m., 1 tablet at 7.00 p.m. from day 1 to day 10."
            }, 
            {
                "arm_group_label": "Oxazepam", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients randomized to the second arm of the study will receive:\nOXAZEPAM (tablets): 60mg at 8.00 a.m., 60mg at 12.00 p.m., 90mg at 7.00 p.m. from day 1 to day 5, 30mg at 8.00 a.m., 30mg at 12.00 p.m., 30mg at 7.00 pm, on days 6 and 7, and 15mg at 8.00 a.m., 15mg at 12.00 p.m., 15mg at 7.00 p.m. from day 8 to day 10;\nplacebo (suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10, (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml)."
            }
        ], 
        "brief_summary": {
            "textblock": "Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome\n      (AWS). Gamma-Hydroxybutyric acid also known as sodium oxybate (SMO) has been tested as a\n      treatment for AWS with encouraging results. Aim of this phase IV, multicenter randomized\n      double-blind, double dummy study is to evaluate the efficacy of SMO in comparison to\n      oxazepam in the treatment of alcohol withdrawal symptoms (AWS)."
        }, 
        "brief_title": "Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome", 
        "completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Alcohol Withdrawal Syndrome", 
            "Alcohol Dependence"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alcoholism", 
                "Substance Withdrawal Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase IV, multicenter randomized (1:1), active drug-controlled study\n      (double-blind, double dummy) with parallel groups evaluating the efficacy of SMO versus\n      oxazepam in the treatment of AWS in alcohol-dependent patients.\n\n      A placebo-controlled design was considered but excluded, given that a gold standard\n      treatment for AWS is available (i.e., BDZs).\n\n      Furthermore, considering that SMO and oxazepam have two different pharmaceutical formulation\n      (suspension and tablets, respectively), a double-dummy design was adopted.\n\n      Thus, all subjects will receive both medications, tablets (oxazepam or placebo) and\n      suspension (SMO or placebo), at the same time."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age range 21-75,\n\n          -  diagnosis of alcohol dependence according to DSM-IV criteria\n\n          -  the presence of AWS as assessed by Clinical Institute Withdrawal Assessment for\n             Alcohol-revised (CIWA-Ar) scale, a scoring system for quantitative evaluation of\n             physical symptoms of AWS.20 Only subjects with a CIWA-Ar score equal to or higher\n             than 10 (defined as moderate or severe AWS requiring pharmacological treatment) were\n             ultimately enrolled in the study.\n\n        Exclusion criteria:\n\n          -  \u226455 kg of body weight;\n\n          -  history of withdrawal fits within 24 hours pre-study;\n\n          -  history of epilepsy or epileptics seizures not properly controlled by established\n             anti-epileptic treatment;\n\n          -  dependence from narcotics, BDZs or other drugs of abuse;\n\n          -  documented pre-existent hypersensitivity to SMO or to BDZs,\n\n          -  renal failure (blood creatinine >2\u20225 mg/dl and/or documented proteinuria >500\n             mg/die),\n\n          -  heart failure,\n\n          -  severe respiratory failure\n\n          -  hepatic encephalopathy stage II-IV;\n\n          -  psychiatric disorders requiring treatment with psychoactive medications before the\n             start of the study;\n\n          -  treatment with clonidine, haloperidol, bromocriptine during the last 3 months prior\n             to participation in the study;\n\n          -  participation to other clinical investigations in the previous month prior to\n             recruitment;\n\n          -  females whose could not assure not to become pregnant during the 1 month period of\n             treatment, and during the subsequent 3 weeks;\n\n          -  subjects without a stable social condition or homeless."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "127", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090504", 
            "org_study_id": "GATE-I"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sodium oxybate (SMO)", 
                "intervention_name": "Sodium Oxybate (SMO)", 
                "intervention_type": "Drug", 
                "other_name": "Gamma-hydroxy butyrate (GHB)"
            }, 
            {
                "arm_group_label": "Oxazepam", 
                "intervention_name": "Oxazepam", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sodium Oxybate", 
                "Oxazepam"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "alcohol withdrawal syndrome", 
            "treatment", 
            "sodium oxybate", 
            "oxazepam"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "state": "AT"
                    }, 
                    "name": "University of Wien"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "BO"
                    }, 
                    "name": "\"G. Fontana\" Centre for the Study and Multidisciplinary Treatment of Alcohol Addiction, Department of Clinical Medicine, University of Bologna"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy", 
                        "state": "Rm", 
                        "zip": "00168"
                    }, 
                    "name": "Catholic University of Rome"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Italy"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "The Gamma Hydroxybutyric Acid in Alcohol-dependence Treatment Efficacy (GATE) I Trial: a Comparative Study Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome", 
        "other_outcome": {
            "description": "Assessment of craving for the study drug.", 
            "measure": "Craving for study drug.", 
            "safety_issue": "No", 
            "time_frame": "day 1, day 10, day 20"
        }, 
        "overall_official": [
            {
                "affiliation": "Department of Psychiatry, University of Wien", 
                "last_name": "Otto Lesch, MD, Prof.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Internal Medicine, Catholic University of Rome", 
                "last_name": "Giovanni Addolorato, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "European Union: European Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary outcome was the reduction of symptoms of AWS reflected by the course of the total CIWA-Ar scores from the start (baseline) to the end of the study (day 10) and to the end of follow up (day 20, 10 days after drugs discontinuation).", 
            "measure": "Efficacy of GHB compared to oxazepam on alcohol withdrawal symptoms", 
            "safety_issue": "No", 
            "time_frame": "day 1, day 10, day 20"
        }, 
        "reference": {
            "PMID": "24283802", 
            "citation": "Skala K, Caputo F, Mirijello A, Vassallo G, Antonelli M, Ferrulli A, Walter H, Lesch O, Addolorato G. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother. 2014 Feb;15(2):245-57. doi: 10.1517/14656566.2014.863278. Epub 2013 Nov 28."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090504"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Catholic University, Italy", 
            "investigator_full_name": "Giovanni Addolorato", 
            "investigator_title": "Professor of Internal Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Secondary outcome variables included the course of alcohol abstinence. In order to confirm daily alcohol abstinence, a breath analyzer was used. In addition, to define those subjects remaining abstinent throughout the whole treatment period, carbohydrate-deficient transferrin (%CDT) was evaluated at the time of screening and at the end of the treatment period.", 
            "measure": "Course of alcohol abstinence", 
            "safety_issue": "Yes", 
            "time_frame": "day 1, day 10, day 20"
        }, 
        "source": "Catholic University of the Sacred Heart", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "CT Pharmaceutical Industries, Sanremo - Italy", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Bologna", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Medical University of Vienna", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Catholic University of the Sacred Heart", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}